These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 25572747)
1. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema. Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747 [TBL] [Abstract][Full Text] [Related]
2. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O; Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922 [TBL] [Abstract][Full Text] [Related]
3. Icatibant as acute treatment for hereditary angioedema in adults. Farkas H Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689 [TBL] [Abstract][Full Text] [Related]
4. First report of icatibant treatment in a pregnant patient with hereditary angioedema. Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898 [TBL] [Abstract][Full Text] [Related]
5. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I; J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444 [TBL] [Abstract][Full Text] [Related]
6. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks. Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903 [TBL] [Abstract][Full Text] [Related]
7. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645 [TBL] [Abstract][Full Text] [Related]
8. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey. Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility. Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136 [TBL] [Abstract][Full Text] [Related]
10. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641 [TBL] [Abstract][Full Text] [Related]
11. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3. Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097 [TBL] [Abstract][Full Text] [Related]
12. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals. Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T; Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study. Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405 [TBL] [Abstract][Full Text] [Related]
14. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema. Piras V; Alves F; Gonçalo M Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975 [TBL] [Abstract][Full Text] [Related]
15. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report. Firinu D; Barca MP; Serusi L; Lorrai MM; Peralta MM; Manconi PE; Del Giacco SR Int J Immunopathol Pharmacol; 2012; 25(1):269-73. PubMed ID: 22507340 [TBL] [Abstract][Full Text] [Related]
16. Current and emerging therapies to prevent hereditary angioedema attacks. Lumry WR Am J Manag Care; 2018 Aug; 24(14 Suppl):S299-S307. PubMed ID: 30132644 [TBL] [Abstract][Full Text] [Related]
17. An evidence based therapeutic approach to hereditary and acquired angioedema. Bork K Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294 [TBL] [Abstract][Full Text] [Related]